Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | BCAT1 | P54687 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9394876 | 0.83 | ATM (0.52) | KMT2AATMLMNATSHRHSD17B10 | |
| SCHEMBL16186175 | 0.83 | KMT2A (0.43) | KMT2AATMLMNATSHRHSD17B10 | |
| SCHEMBL17472101 | 0.82 | ATM (0.48) | KMT2AATMLMNATSHRHSD17B10 | |
| SCHEMBL18269676 | 0.82 | ATM (0.45) | KMT2AATMLMNATSHRHSD17B10 | |
| SCHEMBL25725872 | 0.82 | KMT2A (0.42) | KMT2AATMLMNATSHRHSD17B10 | |
| SCHEMBL6097619 | 0.79 | CA12 (0.51) | KMT2AATMLMNATSHRHSD17B10 | |
| SCHEMBL5281607 | 0.77 | KMT2A (0.47) | KMT2AATMLMNATSHRHSD17B10 | |
| SCHEMBL16884985 | 0.76 | CA12 (0.51) | KMT2AATMLMNATSHRHSD17B10 | |
| SCHEMBL5312084 | 0.75 | LMNA (0.42) | KMT2AATMLMNATSHRHSD17B10 | |
| SCHEMBL26047552 | 0.75 | ATM (0.50) | KMT2AATMLMNATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2023126297-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2023-07-06 | — | — | WO | disclosed |
| WO-2022010951-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022008419-A1 | ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES | BYONDIS B.V. (NL) | 2022-01-13 | — | — | WO | disclosed |
| WO-2022010948-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF FOR THE TREATMENT OF VIRAL DISEASES | CRESCENTA BIOSCIENCES (US) | 2022-01-13 | — | — | WO | disclosed |
| WO-2021263246-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3253745-B1 | COMPOUNDS CONTAINING CARBON-CARBON LINKER AS GPR120 AGONISTS | PIRAMAL ENTPR LTD (IN) | 2021-09-29 | — | — | EP | disclosed |
| WO-2021150645-A1 | NOVEL CELL METABOLISM MODULATING COMPOUNDS AND USES THEREOF | CRESCENTA BIOSCIENCES (US) | 2021-07-29 | — | — | WO | disclosed |
| EP-3191463-B1 | FUSED HETEROCYCLIC COMPOUNDS AS GPR120 AGONISTS | PIRAMAL ENTPR LTD (IN) | 2019-10-30 | — | — | EP | disclosed |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-12-01 | — | — | US | disclosed |
| WO-2013001297-A1 | BINDING INHIBITORS OF THE BETA.TRANSDUCIN REPEAT - CONTAINING PROTEIN | ITI SCOTLAND LIMITED (GB) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | FABP1, FABP4, FABP5 | KMT2A 4004/4885ATM 4881/4885LMNA 2753/4885 |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | GPR119, GPR55, GPR180 | KMT2A 4028/4885ATM 3652/4885LMNA 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.